AB Science: shares climb after drug shows promise
(CercleFinance.com) - AB Science is up more than 3% after announcing that the results of the masitinib study AB12003 on castrate-resistant prostate cancer were presented during the annual meeting of the American Urological Association between 10 and 13 September.
According to this presentation, masitinib at a dose of 6.0 mg/kg/day combined with docetaxel produces a significant benefit for progression-free survival (PFS) in patients with ALP levels equal to or lower than 250 UI/mL. No PFS benefit has been observed in the overall population. The tolerance profile of masitinib associated with docetaxel was acceptable relative to control and in accordance with the known risk profile, with no new safety signals observed. Copyright (c) 2021 CercleFinance.com. All rights reserved. |
26/04/2024 17:39
bioMérieuxle titre monte, un analyste reste à l'achat 26/04/2024 17:31 Alstomdistingué par le prix Hydrogen Mobility 26/04/2024 17:26 Estée Lauderlaboratoire d'innovation IA avec Microsoft 26/04/2024 17:01 Microsoftlaboratoire d'innovation IA avec Estée Lauder 26/04/2024 16:36 Snaples résultats, pour une fois, surprennent à la hausse 26/04/2024 16:27 MersenAmiral Gestion sous les 5% du capital Tous les articles sociétés |
